PMC9479335_01
Schematic diagram of the patient's clinical course indicating treatment, duration, and disease recurrence.
fonc-12-940678-g001.jpg
PMC9479335_01_fonc-12-940678-g001.jpg
f1
Hormone therapy started by tamoxifen for 8 months from June 2015 to February 2016; however, due to some side effects it was switched to letrozole which was consumed for about 2.5 years from February 2016 to July 2018 ( Figure 1 ).
First PET/CT on 26 July 2018. The arrows show a fluorodeoxyglucose (FDG) avidity-standardized uptake value (SUVmax = 9.2) hypo-attenuating lesion with partial necrosis with the left liver lobe, compatible with metastatic disease.
fonc-12-940678-g002.jpg
PMC9479335_01_fonc-12-940678-g002.jpg
f2